Ascletis gains after reporting interim revenues

After weeks of getting hammered against the backdrop of a vaccine scandal and trade war that's weighed generally on Chinese stocks, Ascletis Pharma Inc. (HKSE:1672) gained HK$2.02 (28%) to HK$9.24 on Friday. The move coincides with the release of the biotech's 1H18 results.

Ascletis reported first half total revenues of RMB115.1 million ($17.4 million), up from RMB26.6 million in the prior period. 1H18 sales included RMB26.4 million ($4 million) from sales of HCV drug Ganovo danoprevir, which Ascletis launched in China in June. Ascletis received much of the remainder from Roche (SIX:ROG; OTCQX:RHHBY) in payments related to a 2013 deal granting Ascletis Chinese rights to Ganovo, an HCV NS3/4A protease inhibitor (see "Roche, Ascletis in Chinese Deal for HCV")...